Canopy Growth (CGC) FCF Margin (2019 - 2026)
Canopy Growth (CGC) posted FCF Margin of 23.38% for Q4 2025, down 44.86% sequentially from 16.14% in Q2 2025, and up 1431.0% YoY from 1.53% in Q4 2024.
Canopy Growth (CGC) FCF Margin (2019 - 2026) Analysis & Trends
Canopy Growth has reported FCF Margin for 7 years, with the latest figure at 23.38% in Q4 2025.
- Quarterly FCF Margin rose 1431.0% year-over-year to 23.38% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 14.39% (up 4440.0% YoY) and the FY2026 annual result came in at 111.11%, up 28148.0% from the prior year.
- FCF Margin slipped to 23.38% in Q4 2025 per CGC's latest filing, from 16.14% in the prior quarter.
- Over five years, FCF Margin peaked at 17.59% in Q1 2023 and troughed at 233.28% in Q4 2022.
- A 5-year average of 85.53% and a median of 86.86% in 2024 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2021 and 2022: FCF Margin jumped 65156 bps in 2021, then plunged 12469 bps in 2022.
- Over 5 years, FCF Margin stood at 108.59% in 2021, then plunged by 115 bps to 233.28% in 2022, then soared by 82 bps to 42.2% in 2023, then grew by 11 bps to 37.69% in 2024, then jumped by 38 bps to 23.38% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 23.38%, 16.14%, and 37.69% for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Canopy Growth | 445.49 Mn | 198.48 Mn | 16.08 Mn | -25.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.65% |
| Dec 31, 2025 | -23.38% |
| Jun 30, 2025 | -16.14% |
| Dec 31, 2024 | -37.69% |
| Sep 30, 2024 | -89.60% |
| Jun 30, 2024 | -84.12% |
| Mar 31, 2024 | -30.65% |
| Dec 31, 2023 | -42.20% |
| Sep 30, 2023 | -175.00% |
| Jun 30, 2023 | -141.84% |
| Mar 31, 2023 | 17.59% |
| Dec 31, 2022 | -233.28% |
| Sep 30, 2022 | -94.65% |
| Jun 30, 2022 | -120.34% |
| Mar 31, 2022 | 7.85% |
| Dec 31, 2021 | -108.59% |
| Sep 30, 2021 | -77.14% |
| Jun 30, 2021 | -136.60% |
| Mar 31, 2021 | -153.66% |
| Dec 31, 2020 | -182.09% |